FDA Approves CAR-T Therapies for Early Multiple Myeloma Treatment


The FDA has expanded the approved indications for two groundbreaking CAR-T cell therapies, Abecma and Carvykti, offering new treatment options for patients with multiple myeloma. Bristol Myers Squibb and 2seventy bio’s Abecma is now approved for third-line treatment, while Johnson & Johnson and Legend Biotech’s Carvykti has received the green light for second-line use.

These approvals mark a significant milestone in the fight against multiple myeloma, as CAR-T therapies represent a novel and promising approach to treating this blood cancer. By harnessing the power of a patient’s own immune system, CAR-T therapies have demonstrated impressive efficacy in clinical trials, providing hope for patients who have exhausted other treatment options.

The earlier line approvals for Abecma and Carvykti are expected to expand access to these innovative therapies and improve outcomes for patients with multiple myeloma. As research continues to advance in the field of CAR-T therapy, the potential for further breakthroughs in the treatment of blood cancers and other malignancies remains high.